Mushin, Ma’an
Royal Adelaide Hospital · Baylor College of Medicine · Arrowhead Pharmaceuticals (United States) · Stanford Medicine · Université de Montréal · Stanford University · Icahn School of Medicine at Mount Sinai
2 papers on CoChat
Most cited papers
- Verified
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., et al. (2024) · New England Journal of Medicine
Lipid metabolism and disordersLipoproteins and Cardiovascular Health
Cited by 210
- Verified
Plozasiran (ARO-APOC3), an investigational RNAi, demonstrates robust and durable TG reductions in patients with mixed dyslipidemia, MUIR final results
Vasas, S., Azizad, M., Clifton, P., Rosenson, R., Gaudet, D., Hellawell, J., Chang, T., Melquist, S., Fu, R., Mushin, M., et al. (2024) · Journal of Clinical Lipidology
Lipoproteins and Cardiovascular HealthLipid metabolism and disorders
Cited by 3
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free